BlueRock Therapeutics, a Bayer subsidiary developing stem cell treatments for Parkinson’s disease, has partnered with Rune ...

The ANVS-25002 study is expected to enroll approximately 500 participants with Parkinson’s disease across multiple clinical ...

A new study in the Journal of Neurology offers critical longitudinal insights into how symptoms and functional impacts evolve for individuals with early Parkinson's disease (PD). Led by Jamie Adams, M ...

Deciding if and when to pursue deep brain stimulation (DBS) can be overwhelming for people with Parkinson's disease. While DBS is one of the most effective interventions for movement symptoms, it's ...

Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.

A groundbreaking open-source computer program uses artificial intelligence to analyze videos of patients with Parkinson's disease and other movement disorders. The tool, called VisionMD, helps doctors ...

Fatigue, cognitive changes and sleep disturbances were as important to patients with early Parkinson’s disease as symptoms ...

GEN announces approval in the Netherlands to initiate patient enrollment in April 2026 for the Phase II Proof of ...

Parkinson’s disease is a progressive brain disorder that affects movement, balance, and many aspects of daily life. It occurs when nerve cells in a part of the brain that produces dopamine slowly ...

Objectives Parkinson’s disease (PD) is a complex, progressive neurological disorder with motor and non-motor symptoms. Among the non-motor symptoms, constipation severely affects the patients’ quality ...

When Janet Shipton sat down to write a holiday postcard to her aunt, the then 47-year-old didn’t imagine for a second that it would reveal the first symptom of early onset Parkinson’s. “I was in ...